Intercell Executes Multi-Year Contract for Supply of IXIARO to the United States Military
First sales of IXIARO under this military contract expected soon
This supply contract was negotiated in response to a Request for Proposals (RFP) issued by the DLA in August 2008. The parties were able to move forward to finalize the contract after IXIARO was approved by the Food and Drug Administration on March 30. The major terms of this contract are as follows:
- Exclusive contract for Intercell to supply DLA with all their requirements for JE vaccine
- Five-year contract, with annual options for price modifications
IXIARO was developed by Intercell under an agreement with the Walter Reed Army Institute of Research (WRAIR).
Intercell will directly distribute and market IXIARO to the U.S. military. Novartis Vaccines USA will market and distribute the vaccine to the private market in the U.S.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.